Savient Pharmaceuticals appoints president of Savient Europe


David Veitch takes up the role

David Veitch took over as president of Savient Europe yesterday.

Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management to the US biopharmaceutical firm. He will be responsible for establishing, building and leading Savient\'s European regional organisation to launch and drive the future growth of Krystexxa (pegloticase), a drug for the treatment of chronic gout in adult patients refractory to conventional therapy.

Savient submitted its European Marketing Authorisation Application (MAA) for Krystexxa in May 2011, and anticipates EU approval in the second half of 2012.

Veitch joins Savient with more than 24 years of pharmaceutical industry experience at Bristol- Myers Squibb and SmithKline Beecham Pharmaceuticals, and has extensive knowledge across many therapy areas including: oncology, virology, CV-Metabolism, CNS and immunology.

Most recently he was senior vice president of European marketing and brand commercialisation at Bristol Myers Squibb.

Prior to that, Veitch spent 10 years in a number of leadership positions at Bristol-Myers Squibb.